ABBV-CLS-579 + VEGFR TKI

**ABBV-CLS-579 + VEGFR TKI** is an investigational combination therapy for advanced solid tumors, currently studied specifically in advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-579 is a small molecule inhibitor of PTPN2 and PTP1B, protein tyrosine phosphatases involved in regulating immune responses and potentially tumor cell growth. VEGFR TKI denotes a vascular endothelial growth factor receptor tyrosine kinase inhibitor, designed to block angiogenesis—the formation of new blood vessels that feed tumor growth. The combination aims to improve anti-tumor immune response and disrupt tumor vascularization. The therapy is being explored primarily in subjects with locally advanced or metastatic ccRCC, as well as in broader populations of relapsed or refractory solid tumors. Key developer collaborators are AbbVie and Calico Life Sciences[1][3][6][2].